Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.
2.

Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?

Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):25-31. doi: 10.2174/1381612825666190313140811.

PMID:
31092171
3.

Psychological Functioning of Patients With Inflammatory Bowel Disease.

Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G.

Inflamm Bowel Dis. 2019 Aug 20;25(9):e112. doi: 10.1093/ibd/izz082. No abstract available.

PMID:
31039252
4.

Detection and management of early stage inflammatory bowel disease: an update for clinicians.

Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):547-555. doi: 10.1080/17474124.2019.1605291. Epub 2019 Apr 22.

PMID:
31007098
5.

Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease.

Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S.

Clin Gastroenterol Hepatol. 2019 Apr 14. pii: S1542-3565(19)30415-X. doi: 10.1016/j.cgh.2019.04.025. [Epub ahead of print] Review.

PMID:
30995529
6.

Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease.

Ellul P, Zammit SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, Fiorino G, Torres J, Lopez-Sanroman A, Caruana M, Zammit L, Mantzaris G.

J Crohns Colitis. 2019 May 27;13(6):815. doi: 10.1093/ecco-jcc/jjy221. No abstract available.

PMID:
30951595
7.

Drosophila melanogaster: A Model Organism to Study Cancer.

Mirzoyan Z, Sollazzo M, Allocca M, Valenza AM, Grifoni D, Bellosta P.

Front Genet. 2019 Mar 1;10:51. doi: 10.3389/fgene.2019.00051. eCollection 2019. Review.

8.

Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?

Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.

Curr Pharm Des. 2019;25(1):7-12. doi: 10.2174/1381612825666190312113610.

PMID:
30864505
9.

An Integrated Multilevel Analysis Profiling Biosafety and Toxicity Induced by Indium- and Cadmium-Based Quantum Dots in Vivo.

Allocca M, Mattera L, Bauduin A, Miedziak B, Moros M, De Trizio L, Tino A, Reiss P, Ambrosone A, Tortiglione C.

Environ Sci Technol. 2019 Apr 2;53(7):3938-3947. doi: 10.1021/acs.est.9b00373. Epub 2019 Mar 13.

PMID:
30821457
10.

Inflammation, necrosis, and the kinase RIP3 are key mediators of AAG-dependent alkylation-induced retinal degeneration.

Allocca M, Corrigan JJ, Mazumder A, Fake KR, Samson LD.

Sci Signal. 2019 Feb 12;12(568). pii: eaau9216. doi: 10.1126/scisignal.aau9216.

PMID:
30755477
11.

Biosimilars of adalimumab: the upcoming challenge in IBD.

Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.

Expert Opin Biol Ther. 2019 Jan 2. doi: 10.1080/14712598.2019.1564033. [Epub ahead of print]

PMID:
30601098
12.

'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review.

Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP.

J Crohns Colitis. 2019 Jan 1;13(1):127-137. doi: 10.1093/ecco-jcc/jjy140.

PMID:
30423033
13.

Sub-endocardial and sub-epicardial measurement of myocardial blood flow using 13NH3 PET in man.

Sciagrà R, Milan E, Giubbini R, Kubik T, Di Dato R, Gallo L, Camoni L, Allocca M, Calabretta R.

J Nucl Cardiol. 2018 Sep 20. doi: 10.1007/s12350-018-1445-y. [Epub ahead of print]

PMID:
30238298
14.

Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars.

Pouillon L, Allocca M, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2018 Sep;48(5):574-575. doi: 10.1111/apt.14847. No abstract available.

PMID:
30156324
15.

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study.

Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, Danese S.

J Crohns Colitis. 2018 Nov 28;12(12):1385-1391. doi: 10.1093/ecco-jcc/jjy107.

16.

Can IL-23 be a good target for ulcerative colitis?

Allocca M, Furfaro F, Fiorino G, Gilardi D, D'Alessio S, Danese S.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:95-102. doi: 10.1016/j.bpg.2018.05.016. Epub 2018 May 23. Review.

PMID:
30060945
17.

Evolving strategies and goals of treatment in ulcerative colitis.

Allocca M, Peyrin-Biroulet L, Danese S.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:1-2. doi: 10.1016/j.bpg.2018.07.001. No abstract available.

PMID:
30060932
18.

PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.

Expert Opin Investig Drugs. 2018 Jul;27(7):623-629. doi: 10.1080/13543784.2018.1494722. Epub 2018 Jul 16. Review.

PMID:
29985060
19.

Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making.

Allocca M, Fiorino G, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L, Danese S.

J Crohns Colitis. 2018 Nov 15;12(11):1280-1287. doi: 10.1093/ecco-jcc/jjy093.

PMID:
29982361
20.

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.

D'Amico F, Fiorino G, Furfaro F, Allocca M, Danese S.

Expert Opin Investig Drugs. 2018 Jul;27(7):595-599. doi: 10.1080/13543784.2018.1492547. Epub 2018 Jul 6. Review.

PMID:
29938545
21.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155.

PMID:
29788318
22.

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S.

Inflamm Bowel Dis. 2018 Feb 15;24(3):601-606. doi: 10.1093/ibd/izx086.

PMID:
29462398
23.

Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.

Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, Danese S.

Eur J Gastroenterol Hepatol. 2018 Mar;30(3):316-322. doi: 10.1097/MEG.0000000000001074. Review.

PMID:
29351114
24.

Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.

Fiorino G, Correale C, Radice S, Allocca M, Furfaro F, Gilardi D, Nagore D, Del Rio L, Pascual J, Martínez A, Danese S.

Aliment Pharmacol Ther. 2017 Nov;46(9):903-905. doi: 10.1111/apt.14262. No abstract available.

25.

PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration.

Allocca M, Corrigan JJ, Fake KR, Calvo JA, Samson LD.

Oncotarget. 2017 Aug 3;8(40):68707-68720. doi: 10.18632/oncotarget.19844. eCollection 2017 Sep 15.

26.

Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea.

Gilardi D, Fiorino G, Furfaro F, Alfieri MF, Orlandi I, Allocca M, Danese S.

Minerva Gastroenterol Dietol. 2017 Dec;63(4):319-326. doi: 10.23736/S1121-421X.17.02411-4.

PMID:
28927248
27.

Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.

Allocca M, Landi R, Bonovas S, Fiorino G, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, Danese S.

Digestion. 2017;96(3):166-172. doi: 10.1159/000480231. Epub 2017 Sep 14.

PMID:
28903094
28.

Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?

Allocca M, Fiorino G, Danese S.

Dig Dis Sci. 2017 Nov;62(11):2964-2965. doi: 10.1007/s10620-017-4693-9. No abstract available.

PMID:
28776140
29.

ALKBH7 drives a tissue and sex-specific necrotic cell death response following alkylation-induced damage.

Jordan JJ, Chhim S, Margulies CM, Allocca M, Bronson RT, Klungland A, Samson LD, Fu D.

Cell Death Dis. 2017 Jul 20;8(7):e2947. doi: 10.1038/cddis.2017.343.

30.

Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience.

Allocca M, Bonifacio C, Fiorino G, Spinelli A, Furfaro F, Balzarini L, Bonovas S, Danese S.

Dig Liver Dis. 2017 Aug;49(8):872-877. doi: 10.1016/j.dld.2017.03.012. Epub 2017 Mar 30.

PMID:
28416240
31.

The safety of biological pharmacotherapy for the treatment of ulcerative colitis.

Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S.

Expert Opin Drug Saf. 2017 Apr;16(4):437-443. doi: 10.1080/14740338.2017.1298743. Epub 2017 Mar 10. Review.

PMID:
28279079
32.

Dissecting common and divergent molecular pathways elicited by CdSe/ZnS quantum dots in freshwater and marine sentinel invertebrates.

Ambrosone A, Roopin M, Pelaz B, Abdelmonem AM, Ackermann LM, Mattera L, Allocca M, Tino A, Klapper M, Parak WJ, Levy O, Tortiglione C.

Nanotoxicology. 2017 Mar;11(2):289-303. doi: 10.1080/17435390.2017.1295111.

PMID:
28248594
33.

IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.

Furfaro F, Gilardi D, Allocca M, Cicerone C, Correale C, Fiorino G, Danese S.

Expert Rev Clin Immunol. 2017 May;13(5):457-467. doi: 10.1080/1744666X.2017.1279055. Epub 2017 Jan 13. Review.

PMID:
28067059
34.

Parp1 protects against Aag-dependent alkylation-induced nephrotoxicity in a sex-dependent manner.

Calvo JA, Allocca M, Fake KR, Muthupalani S, Corrigan JJ, Bronson RT, Samson LD.

Oncotarget. 2016 Jul 19;7(29):44950-44965. doi: 10.18632/oncotarget.10440.

35.

Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?

Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S.

Curr Drug Targets. 2018;19(7):748-756. doi: 10.2174/1389450117666160527142719.

PMID:
27231106
36.

Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.

Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14. Review.

PMID:
27189910
37.

Perception of Reproductive Health in Women with Inflammatory Bowel Disease.

Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, Fiorino G, Torres J, Lopez-Sanroman A, Caruana M, Zammit L, Mantzaris G.

J Crohns Colitis. 2016 Aug;10(8):886-91. doi: 10.1093/ecco-jcc/jjw011. Epub 2016 Jan 18. Erratum in: J Crohns Colitis. 2019 May 27;13(6):815.

PMID:
26783343
38.

Emerging therapeutic targets and strategies in Crohn's disease.

Furfaro F, Fiorino G, Allocca M, Gilardi D, Danese S.

Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):735-44. doi: 10.1586/17474124.2016.1142372. Epub 2016 Feb 16. Review.

PMID:
26766496
39.

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S.

Medicine (Baltimore). 2016 Jan;95(2):e2308. doi: 10.1097/MD.0000000000002308. Review.

40.

Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Bravatà I, Allocca M, Fiorino G, Danese S.

Curr Opin Pharmacol. 2015 Dec;25:67-71. doi: 10.1016/j.coph.2015.11.007. Review.

PMID:
26687159
41.

Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box?

Fiorino G, Allocca M, Danese S.

Clin Gastroenterol Hepatol. 2015 Oct;13(10):1767-9. doi: 10.1016/j.cgh.2015.06.004. Epub 2015 Jun 16. No abstract available.

PMID:
26091737
42.

Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease.

Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S.

J Crohns Colitis. 2015 Aug;9(8):633-9. doi: 10.1093/ecco-jcc/jjv080. Epub 2015 May 9.

PMID:
25958059
43.

Golimumab: clinical update on its use for ulcerative colitis.

Gilardi D, Fiorino G, Allocca M, Bravatà I, Danese S.

Drugs Today (Barc). 2015 Mar;51(3):171-84. doi: 10.1358/dot.2015.51.3.2298240. Review.

PMID:
25876561
44.

Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.

Fernandes C, Allocca M, Danese S, Fiorino G.

Immunotherapy. 2015;7(2):175-90. doi: 10.2217/imt.14.105. Review.

PMID:
25713992
45.

New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.

Bravatà I, Fiorino G, Allocca M, Repici A, Danese S.

Scand J Gastroenterol. 2015 Jan;50(1):113-20. doi: 10.3109/00365521.2014.993700. Review.

PMID:
25523561
46.

Aag-initiated base excision repair promotes ischemia reperfusion injury in liver, brain, and kidney.

Ebrahimkhani MR, Daneshmand A, Mazumder A, Allocca M, Calvo JA, Abolhassani N, Jhun I, Muthupalani S, Ayata C, Samson LD.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4878-86. doi: 10.1073/pnas.1413582111. Epub 2014 Oct 27.

47.

Iron deficiency: the hidden miscreant in inflammatory bowel disease.

Allocca M, Fiorino G, Danese S.

Curr Drug Targets. 2014;15(11):1011-9. Review.

PMID:
25213175
48.

Review article: optimal preparation for surgery in Crohn's disease.

Spinelli A, Allocca M, Jovani M, Danese S.

Aliment Pharmacol Ther. 2014 Nov;40(9):1009-22. doi: 10.1111/apt.12947. Epub 2014 Sep 10. Review.

49.

Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.

Allocca M, Fiorino G, Vermeire S, Reinisch W, Cataldi F, Danese S.

Expert Rev Clin Immunol. 2014 Jul;10(7):885-95. doi: 10.1586/1744666X.2014.917962. Epub 2014 May 12. Review.

PMID:
24813675
50.

Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?

Gilardi D, Fiorino G, Genua M, Allocca M, Danese S.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):835-46. doi: 10.1586/17474124.2014.917954. Epub 2014 May 12. Review.

PMID:
24813226

Supplemental Content

Loading ...
Support Center